ST-Segment Elevation Myocardial Infarction in the Time of COVID-19

This study cites the experience of 6 sites during the first month of the COVID-19 pandemic in New York. All patients included had a confirmed diagnosis of coronavirus infection and also ST-segment elevation on electrocardiography.

Eighteen patients met these criteria. We are used to large randomized studies; consequently, this small registry of less than 20 people seems to fall short, but it is all we have so far.

The mean age for the studied subjects was 63 years old and most patients were male. Only a third of this group experienced chest pain along the ST-segment elevation.

Half the patients admitted with COVID-19 symptoms had ST-segment elevation in the initial electrocardiography, while all others developed it during hospitalization.

Half the group (9 patients) ended up in the cath lab; 6 patients had obstructive lesions and 5 underwent angioplasty.


Read also: Procedural Rescheduling Criteria in the Pandemic Era.


About half these patients had a “conventional” ST-segment elevation myocardial infarction; the other half experienced myocardial injury without any associated coronary disease.

Most included patients (72%) passed away at the hospital (4 patients with coronary disease and 9 with myocardial injury without coronary lesions).

In this series of patients affected by the new coronavirus and ST-segment elevation, there was a high prevalence of nonobstructive disease and a high mortality rate.


Read also: Reperfusion in the Time of COVID-19. What Has Changed?


Myocardial injuries in patients with COVID-19 may result from plaque rupture, cytokine storm, hypoxic injury, coronary spasm, microthrombi, or direct endothelial injury.

All patients had interstitial edema on magnetic resonance imaging.

10-1056-NEJMc2009020

Original Title: ST-Segment Elevation in Patients with Covid-19 — A Case Series.

Reference: Sripal Bangalore et al. The New England Journal of Medicine, article in press.   


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...